Study guide

CSCR and the pachychoroid spectrum

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

CSCR and the pachychoroid spectrum

Key Takeaways Explain This Topic AI

CSCR involves choroidal and RPE dysfunction, with steroid exposure and systemic context relevant to assessment.

A smokestack is a characteristic leakage pattern rather than a separate treatment indication.

PLACE supports half-dose PDT for the studied chronic disease, while VICI did not establish eplerenone as effective routine treatment.

Last updated: October 2026

The Pachychoroid Disease Spectrum Concept

The introduction of Enhanced Depth Imaging Optical Coherence Tomography (EDI-OCT) and long-wavelength Swept-Source OCT (SS-OCT) revolutionized our understanding of choroidal anatomy, giving rise to the modern concept of the pachychoroid disease spectrum (derived from the Greek pachy , meaning "thick").

Defining Morphological Hallmarks of Pachychoroid

The pachychoroid phenotype is characterized by four cardinal pathological criteria:

Choroidal morphology: Dilated outer choroidal vessels, attenuation of inner layers and regional thickness patterns support pachychoroid disease. Absolute thickness depends on age, axial length and other factors; 300–350 micrometres is not a compulsory diagnostic cutoff.

Pathologic Haller Layer Pachyvessels: Marked, asymmetric engorgement, ectasia, and tortuosity of the large venous and arteriolar vessels residing in the outer choroidal layer (Haller layer), known as "pachyvessels" .

Choriocapillaris Compression and Atrophy: The massively expanded Haller layer pachyvessels physically displace and compress the overlying middle vascular layer (Sattler layer) and inner capillary layer ( choriocapillaris ). This mechanical compression produces severe localized attenuation, hypoperfusion, and ischemic loss of the choriocapillaris.

Overlying RPE Dysfunction: Ischemia and chronic hydrostatic pressure gradients from the underlying pachyvessels cause metabolic failure of the overlying retinal pigment epithelium (RPE), leading to focal pigment mottling, micro-rips, and outer blood-retinal barrier (BRB) breakdown.

The Evolutionary Continuum of Pachychoroid Disorders

The pachychoroid spectrum represents an evolutionary disease spectrum spanning four interconnected entities:

1. Pachychoroid Pigment Epitheliopathy (PPE): Considered the forme fruste and earliest stage of the spectrum. Characterized by focal or multifocal areas of RPE hypertrophy, hyperplasia, or atrophy located directly above dilated Haller layer pachyvessels, in the complete absence of subretinal fluid or history of CSCR. Often identified in the asymptomatic fellow eye of patients presenting with unilateral CSCR.

2. Central Serous Chorioretinopathy (CSCR): Characterized by active, localized neurosensory retinal detachment involving the fovea, frequently accompanied by small, focal serous pigment epithelial detachments (PEDs), driven by choroidal vascular hyperpermeability.

3. Pachychoroid Neovasculopathy (PNV): Chronic choriocapillaris ischemia and persistent outer retinal hypoxia over pachyvessels stimulate the growth of Type 1 macular neovascularisation (MNV) beneath the RPE. Unlike conventional neovascular AMD, PNV occurs in relatively young or middle-aged patients without drusen or typical AMD genetics, exhibiting shallow irregular PEDs on OCT.

4. Polypoidal Choroidal Vasculopathy (PCV / Aneurysmal Type 1 Neovascularisation): In eyes with longstanding PNV or primary pachychoroid congestion, high intravascular shear stresses induce aneurysmal dilatation of the abnormal vascular branches, forming terminal polypoidal ectasias. PCV manifests with extensive serosanguineous PEDs and vitreoretinal haemorrhages.

Pathophysiology and Systemic Risk Factors of CSCR

Central serous chorioretinopathy predominantly impacts individuals between 25 and 55 years of age, demonstrating a striking male preponderance (male-to-female ratio ~6:1) .

The Pathophysiological Sequence

The development of CSCR follows a precise biomechanical sequence: Sympathetic / Glucocorticoid Surge ⟹ Choroidal Venous Hypertension ⟹ Pachyvessel Hyperpermeability ⟹ RPE Barrier Micro-Rip ⟹ Neurosensory Retinal Detachment \text{Sympathetic / Glucocorticoid Surge} \implies \text{Choroidal Venous Hypertension} \implies \text{Pachyvessel Hyperpermeability} \implies \text{RPE Barrier Micro-Rip} \implies \text{Neurosensory Retinal Detachment} Sympathetic / Glucocorticoid Surge ⟹ Choroidal Venous Hypertension ⟹ Pachyvessel Hyperpermeability ⟹ RPE Barrier Micro-Rip ⟹ Neurosensory Retinal Detachment

Choroidal Vasomotor Dysregulation & Hyperpermeability: Sympathetic hyperactivation and elevated mineralocorticoid/glucocorticoid signaling produce severe focal stasis, vasoconstriction, and downstream venous hypertension within the vortex vein ampullae and Haller layer vessels. This elevated hydrostatic pressure causes widespread leakage of plasma and macromolecules into the choroidal stroma, visible on ICGA as choroidal vascular hyperpermeability.

RPE Hydrostatic Overload & Outer BRB Breakdown: The accumulation of interstitial fluid markedly increases extravascular pressure within the choroid. Hydrostatic pressure exerts continuous mechanical stress on the overlying RPE monolayer. When this exceeds the adhesive tensile strength of RPE intercellular tight junctions ( zonula occludens , claudin-19), focal "micro-rips" or zones of functional decompensation breach the outer blood-retinal barrier.

Serous Subretinal Fluid Accumulation: Fluid is forced into the potential subretinal space between the RPE apical microvilli and photoreceptor outer segments, creating a circular, dome-shaped neurosensory retinal detachment .

Systemic Risk Factors: The Cardinal Role of Corticosteroids

Exogenous Corticosteroids (The Cardinal Risk Factor): Exposure to exogenous steroids—administered via ANY route (oral, intravenous, intra-articular, inhaled, intranasal sprays, topical cutaneous creams, or periocular/ocular formulations)—is the single most potent independent trigger of CSCR. Corticosteroids upregulate endothelial mineralocorticoid receptors, promote choroidal hyperpermeability, impair RPE tight junction integrity, and impede RPE fluid resorption.

Caution

Review corticosteroid exposure in CSCR: Corticosteroid exposure can trigger or worsen CSCR and should not be prescribed as its treatment. Review all routes of exposure and discuss reduction or alternatives with the treating clinician when feasible. Do not abruptly stop medically necessary systemic treatment. Distinguish CSCR from inflammatory choroidal disease before prescribing steroids; the diagnosis changes the management.

Endogenous Hypercortisolemia: Pathologically elevated endogenous cortisol (Cushing syndrome, adrenal adenomas).

Psychosocial Stress & Type A Personality: Elevated circulating catecholamines and sympathetic adrenergic tone.

Sleep Disorders: Obstructive sleep apnoea (OSA), shift-work sleep disruptions.

Other Associations: Pregnancy (third trimester, mediated by endogenous cortisol and progesterone), Helicobacter pylori infection, and phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, tadalafil).

Multimodal Diagnostic Imaging in CSCR

Accurate diagnosis and differentiation of CSCR require multimodal retinal imaging:

1. Enhanced Depth Imaging & Swept-Source OCT (EDI-OCT / SS-OCT)

Subretinal Fluid (SRF): Cross-sectional OCT reveals a smooth, dome-shaped elevation of the neurosensory retina separated from the RPE by an optically clear, hyporeflective fluid space.

Elongated Photoreceptor Outer Segments: In acute CSCR, photoreceptor outer segments detached from the RPE can no longer be phagocytosed. They become swollen, elongated, and hyperreflective ( "shaggy photoreceptors" ). In chronic detachment, outer segments fragment into granular subretinal debris.

Pachychoroid Signs: Markedly thickened subfoveal choroid with dilated, hyporeflective Haller vessels compressing the choriocapillaris, and small, irregular, shallow serous pigment epithelial detachments (PEDs).

Fibrinous Subretinal Exudate: Hyperreflective sheets or mounds within the subretinal fluid space, representing fibrin leakage across severe RPE breakdowns.

2. Fundus Fluorescein Angiography (FA)

Angiographic Pattern Relative Frequency Morphological Characteristics & Hemodynamics

Expansile Dot ("Ink-Blot") Pattern ≈ 80 % \approx 80\% ≈ 80% to 85 % 85\% 85% of cases A solitary or few tiny punctate hyperfluorescent spots appearing in the early transit phase that progressively enlarge and increase in intensity concentrically throughout the late frames, without changing shape.

Smokestack pattern Less common than inkblot leakage Dye extends vertically then spreads laterally. The appearance describes leakage; a single thermal-convection explanation is not established.

Chronic Atrophic Tracts ("Guttering") Seen in chronic / recurrent CSCR Gravitational descending tracts of transmission window hyperfluorescence (RPE atrophy) extending downward from the posterior pole toward the inferior equator, representing historical fluid drainage pathways.

3. Indocyanine Green Angiography (ICGA)

ICGA is the gold-standard modality for visualizing the underlying choroidal vascular pathology:

Early Phase: Demonstrates areas of delayed, irregular, or patchy choroidal filling.

Mid Phase ( 5 − 15 min 5-15\,\text{min} 5 − 15 min ): Reveals diffuse, multifocal zones of intense choroidal vascular hyperpermeability , with hazy leakage blurring the margins of engorged pachyvessels.

Late Phase ( > 20 min >20\,\text{min} > 20 min ): Punctate hyperfluorescent spots and residual hyperfluorescent plaques at sites of choroidal congestion, alongside hypofluorescent wash-out halos.

Natural History and Evidence-Based Management

Acute CSCR often improves spontaneously, but recurrence, chronic fluid and outer-retinal atrophy can impair vision. Duration, prior episodes, fellow-eye status, occupational needs and imaging guide management. There is no compulsory observation period for every patient.

Review all steroid exposure, including inhaled, nasal, topical and systemic preparations. Coordinate reduction or alternatives with the prescribing clinician when possible; never abruptly stop medically necessary steroid therapy. Discuss smoking, sleep and associated health concerns without promising that modifying stress will cure the disease.

For persistent or recurrent CSCR, reduced-setting verteporfin photodynamic therapy (PDT) can be considered after excluding neovascularisation. PLACE compared half-dose PDT with high-density subthreshold micropulse laser. Complete subretinal-fluid resolution was 51.2% versus 13.8% at 6–8 weeks and 67.2% versus 28.8% at 7–8 months. These results do not directly establish identical effectiveness of half-fluence PDT, which is a different protocol. Treatment localisation and dose follow specialist imaging and safety criteria.

VICI found no meaningful benefit of eplerenone over placebo for chronic CSCR; it is not a routine fallback when PDT is unavailable. Anti-VEGF is used when secondary neovascularisation is present rather than for uncomplicated CSCR solely because fluid is visible. Selected extrafoveal focal leakage may be considered for laser, with a scotoma/expansion risk and avoidance of foveal injury.

Follow vision and OCT fluid/outer-retinal integrity and discuss recurrence symptoms. Pachychoroid includes several overlapping phenotypes, but a fixed choroidal-thickness cutoff does not define all cases and patients do not inevitably progress through a single sequence.